Literature DB >> 12176901

A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL).

Urban Novak1, Elisabeth Oppliger Leibundgut, Jörg Hager, Dominique Mühlematter, Martine Jotterand, Celine Besse, Nicolas Leupin, Daniel Ratschiller, Jeanette Papp, Gina Kearsey, Stefan Aebi, Hans Graber, Rolf Jaggi, Jean-Marc Lüthi, Sandrine Meyer-Monard, Mark Lathrop, Andreas Tobler, Martin F Fey.   

Abstract

The most frequent chromosomal aberrations in B-cell chronic lymphocytic leukemia (B-CLL) are deletions on 13q, 11q, and 17p, and trisomy 12, all of which are of prognostic significance. Conventional cytogenetic analysis and fluorescence in situ hybridization (FISH) are used for their detection, but cytogenetic analysis is hampered by the low mitotic index of B-CLL cells, and FISH depends on accurate information about candidate regions. We used a set of 400 highly informative microsatellite markers covering all chromosomal arms (allelotyping) and automated polymerase chain reaction (PCR) protocols to screen 46 patients with typical B-CLL for chromosomal aberrations. For validation, we compared data with our conventional karyotype results and fine mapping with conventional single-site PCR. All clonal cytogenetic abnormalities potentially detectable by our microsatellite PCR (eg, del13q14 and trisomy 12) were picked up. Allelotyping revealed additional complex aberrations in patients with both normal and abnormal B-CLL karyotypes. Aberrations detectable in the samples with our microsatellite panel were found on almost all chromosomal arms. We detected new aberrant loci in typical B-CLL, such as allelic losses on 1q, 9q, and 22q in up to 25% of our patients, and allelic imbalances mirroring chromosomal duplications, amplifications, or aneuploidies on 2q, 10p, and 22q in up to 27% of our patients. We conclude that allelotyping with our battery of informative microsatellites is suitable for molecular screening of B-CLL. The technique is well suited for analyses in clinical trials, it provides a comprehensive view of genetic alterations, and it may identify new loci with candidate genes relevant in the molecular biology of B-CLL.

Entities:  

Mesh:

Year:  2002        PMID: 12176901

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 2.  Genetic alterations in chronic lymphocytic leukaemia.

Authors:  Llorenç Coll-Mulet; Joan Gil
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

Review 3.  New molecular methods for classification, diagnosis and therapy prediction of hematological malignancies.

Authors:  Agnes Zvara; László Hackler; Zsolt B Nagy; Tamás Micsik; László G Puskás
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 2.874

4.  Microsatellite instability in patients with chronic B-cell lymphocytic leukaemia.

Authors:  E Niv; Y Bomstein; M Yuklea; M Lishner
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

5.  New Recurrent Structural Aberrations in the Genome of Chronic Lymphocytic Leukemia Based on Exome-Sequencing Data.

Authors:  Adrián Mosquera Orgueira; Beatriz Antelo Rodríguez; José Ángel Díaz Arias; Marta Sonia González Pérez; José Luis Bello López
Journal:  Front Genet       Date:  2019-09-20       Impact factor: 4.599

Review 6.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

7.  Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia.

Authors:  M Schwaederlé; E Ghia; L Z Rassenti; M Obara; M L Dell'Aquila; J F Fecteau; T J Kipps
Journal:  Leukemia       Date:  2013-01-22       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.